• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    11/27/23 8:06:58 AM ET
    $APLM
    $COCH
    $IMPL
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $APLM alert in real time by email

    Gainers

    • Redhill Biopharma (NASDAQ:RDHL) shares rose 118.7% to $0.69 during Monday's pre-market session. The market value of their outstanding shares is at $7.6 million.
    • Tharimmune (NASDAQ:THAR) stock moved upwards by 39.13% to $4.0. The market value of their outstanding shares is at $2.8 million.
    • Apollomics (NASDAQ:APLM) stock rose 33.37% to $1.33. The company's market cap stands at $119.0 million.
    • 60 Degrees (NASDAQ:SXTP) shares moved upwards by 23.67% to $0.7. The market value of their outstanding shares is at $4.0 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares moved upwards by 17.58% to $0.33. The market value of their outstanding shares is at $8.4 million.
    • Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 12.07% to $15.69. The market value of their outstanding shares is at $859.3 million.

    Losers

    • Impel Pharmaceuticals (NASDAQ:IMPL) shares decreased by 17.7% to $0.69 during Monday's pre-market session. The company's market cap stands at $16.6 million.
    • Nuwellis (NASDAQ:NUWE) stock fell 16.69% to $0.5. The company's market cap stands at $1.6 million.
    • Envoy Medical (NASDAQ:COCH) shares decreased by 10.57% to $1.1. The market value of their outstanding shares is at $21.5 million.
    • Kura Oncology (NASDAQ:KURA) stock decreased by 8.79% to $8.72. The market value of their outstanding shares is at $647.6 million.
    • SenesTech (NASDAQ:SNES) stock fell 7.84% to $2.0.
    • Kiora Pharmaceuticals (NASDAQ:KPRX) shares declined by 7.84% to $0.51. The market value of their outstanding shares is at $3.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM
    $COCH
    $IMPL
    $KPRX

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Olema Pharmaceuticals Inc.
    $OLMA
    10/8/2025$20.00Buy
    Guggenheim
    Kura Oncology Inc.
    $KURA
    9/4/2025Neutral
    Guggenheim
    Olema Pharmaceuticals Inc.
    $OLMA
    8/12/2025$20.00 → $21.00Buy
    Citigroup
    Kura Oncology Inc.
    $KURA
    2/6/2025Buy → Neutral
    BTIG Research
    Kura Oncology Inc.
    $KURA
    10/24/2024$27.00Buy
    UBS
    Kura Oncology Inc.
    $KURA
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    More analyst ratings

    $APLM
    $COCH
    $IMPL
    $KPRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Olema Pharmaceuticals Inc.

    SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/6/26 10:05:20 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Kura Oncology Inc.

    10-K - Kura Oncology, Inc. (0001422143) (Filer)

    3/5/26 7:31:11 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Daniels Eric Joseph covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.90% to 26,137 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/6/26 2:03:53 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Strem Brian M. covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.52% to 45,865 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/6/26 2:03:29 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Mitchell Shawnte exercised 40,000 shares at a strike of $4.37, sold $945,750 worth of shares (39,767 units at $23.78) and sold $5,753 worth of Comon Stock (233 units at $24.69) (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    3/5/26 8:00:07 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(

    3/6/26 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

    – KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical data milestones expected across AML and solid tumor programs – – Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with

    3/5/26 6:31:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Olema Pharmaceuticals with a new price target

    Stifel initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $48.00

    2/11/26 7:52:37 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Olema Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of Olema Pharmaceuticals with a rating of Overweight and set a new price target of $40.00

    1/7/26 9:13:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Olema Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    10/8/25 8:35:33 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    $COCH
    $IMPL
    $KPRX
    Financials

    Live finance-specific insights

    View All

    Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

    – KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical data milestones expected across AML and solid tumor programs – – Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with

    3/5/26 6:31:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura's management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Investors section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceuti

    2/26/26 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care